Opinion

Video

Use of Bone Protection Agents

Panelists discuss how the PEACE-3 trial explores the efficacy of combining radium-223 with enzalutamide in advanced prostate cancer, highlighting its potential to enhance therapeutic outcomes and survival rates.

Do you mandate for an mcrpc that all your patients on a bone health agent and antiresorptive, regardless of the therapy, and regardless of whether they have bone lesions?

Related Videos
Related Content